Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "BCG Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.
The global BCG (Bacillus Calmette-Guérin) vaccine market continues to evolve as it plays a pivotal role in combating the scourge of tuberculosis (TB), highlighted by the latest industry research that delves into its expanding scope.
Valued at USD 145.56 million in 2022, this market is projected to demonstrate a notable Compound Annual Growth Rate (CAGR) of 5.90% through the end of 2028. In an era of heightened public health awareness, the BCG vaccine market remains integral to the worldwide efforts aimed at reducing the impact of TB, a disease that predominantly afflicts lungs and is highly prevalent in resource-limited areas.
Among the key trends influencing growth are the marked rise in TB cases in developing and under-developed nations, sparking concerted drives for better vaccine coverage. With burgeoning birth rates across the globe, the target population for these vaccines is simultaneously expanding. North America stands out as a significant player, retaining a robust demand for BCG vaccines to safeguard at-risk groups, backed by an advanced healthcare system and innovative research and development initiatives.
The BCG vaccine's enduring legacy and its increasing application in diverse healthcare strategies emphasize its crucial position within the medical landscape. This market's trajectory is fundamentally shaped by strategies directed at achieving comprehensive TB prevention, enhanced public health protocols, and an ever-growing focus to bridge immunization gaps.
In the wake of emergent and drug-resistant TB strains, the industry's attention is pivoting towards the development of vaccines with broader protection and greater efficacy. This focus on innovation and adaptability is key to navigating challenges such as supply chain disruptions and the limited effectiveness of current vaccines in certain demographics or against particular TB strains.
Segmented insights offered within the research highlight the dominance of Immune BCG vaccines, owing to their established effectiveness and extensive global usage in TB prevention. The implications of these market dynamics extend to TB patients and at-risk populations, heralding a period of assertive measures aimed at curbing TB's reach through strategic vaccination campaigns. Additionally, the application potential of BCG vaccines in addressing other medical conditions like bladder cancer unveils new market frontiers.
Regional analysis underscores the influential role North America plays in this market segment, with comprehensive public health strategies and heightened research activities informing its leadership. The demand for BCG vaccines in North America is further buttressed by travel recommendations and the regional focus on healthcare workers' safety and global health security.
With retrospective regard to the market's advancements, substantial distribution channels, including hospitals and clinics, assure widespread availability of BCG vaccines, ushering in progressive healthcare paradigms where disease prevention is accessible and widespread. Investment in healthcare infrastructure and global partnerships stands pivotal in confronting TB on a large scale, with this report offering a lens into the industry's comprehensive endeavors and the promising future depicted by the global BCG vaccines market.
BCG Vaccines Market Trends, Drivers, and Challenges
- In-depth research presents Immune BCG as a leading product owing to historical efficacy and global adoption.
- Rising incidence of tuberculosis and increasing birth rates cited as primary market drivers worldwide.
- Supply chain disruptions and limited vaccine efficacy against new TB strains emerge as notable industry challenges.
This research highlights the multifaceted nature of the BCG vaccines market, providing an authoritative resource for healthcare professionals, policymakers, and stakeholders actively engaged in TB prevention and control.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 190 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $145.56 Million |
| Forecasted Market Value (USD) by 2028 | $204.13 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
Report Scope:
In this report, the Global BCG Vaccines Market has been segmented into the following categories:
BCG Vaccines Market, By Product:
- Immune BCG
- Therapy BCG
BCG Vaccines Market, By Application:
- Tuberculosis
- Bladder Cancer
BCG Vaccines Market, By Distribution Channel:
- Hospitals
- Clinics
- Others
Companies Profiled:
- Serum Institute of India Pvt. Ltd.
- GreenSignal Bio Pharma Ltd
- Taj Pharmaceuticals Limited
- Japan BCG Laboratory
- Merck & Co., Inc.
- Microgen LLC
- Biomed Lublin S.A.
- BCG Vaccine Laboratory
- China Biotechnology Co., Ltd.
- AJ Biologics Sdn Bhd
For more information about this report visit https://www.researchandmarkets.com/r/xoj12v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
